41. Giant cell arteritis Clinical trials / Disease details

Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03711448 (ClinicalTrials.gov)	January 7, 2019	15/10/2018	Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis	Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis	Patients Relapsing Refractory Giant Cell Arteritis	Drug: prednisone treatment;Drug: prednisone and ustekinumab treatment;Other: questionnaires;Biological: Blood samples	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	38	Phase 2	France
2	NCT02955147 (ClinicalTrials.gov)	December 1, 2016	31/10/2016	Ustekinumab for the Treatment of Giant Cell Arteritis	Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis	Giant Cell Arteritis;Temporal Arteritis;Horton's Disease	Drug: Ustekinumab;Drug: Prednisone	Massachusetts General Hospital	NULL	Terminated	50 Years	N/A	All	13	Phase 1/Phase 2	United States